{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:45:48Z","timestamp":1770511548962,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s13555-016-0133-6","type":"journal-article","created":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T05:55:15Z","timestamp":1468821315000},"page":"427-436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Superior Efficacy with Ivermectin 1% Cream Compared to Metronidazole 0.75% Cream Contributes to a Better Quality of Life in Patients with Severe Papulopustular Rosacea: A Subanalysis of the Randomized, Investigator-Blinded ATTRACT Study"],"prefix":"10.1007","volume":"6","author":[{"given":"Martin","family":"Schaller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Dirschka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lajos","family":"Kem\u00e9ny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Briantais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Jacovella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,18]]},"reference":[{"issue":"3","key":"133_CR1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/jdv.13556","volume":"30","author":"J Tan","year":"2016","unstructured":"Tan J, Sch\u00f6fer H, Araviiskaia E, Audibert F, Kerrouche N, Berg M, RISE study group. Prevalence of rosacea in the general population of Germany and Russia\u2014the RISE study. J Eur Acad Dermatol Venereol. 2016;30(3):428\u201334.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"133_CR2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jaad.2004.01.048","volume":"50","author":"J Wilkin","year":"2004","unstructured":"Wilkin J, Dahl M, Detmar M, et al. National Rosacea Society Expert Committee. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50(6):907\u201312.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"133_CR3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2133.2010.09894.x","volume":"163","author":"B Aksoy","year":"2010","unstructured":"Aksoy B, Altaykan-Hapa A, Egemen D, Karag\u00f6z F, Atakan N. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol. 2010;163(4):719\u201325.","journal-title":"Br J Dermatol"},{"key":"133_CR4","unstructured":"European Commission. Antimicrobial resistance\u2014action at EU Level. http:\/\/ec.europa.eu\/dgs\/health_food-safety\/amr\/action_eu\/index_en.htm . Accessed 12 Apr 2016."},{"key":"133_CR5","unstructured":"World Health Organization. Global action plan on antimicrobial resistance. http:\/\/www.who.int\/drugresistance\/global_action_plan\/en\/ . Accessed 12 Apr 2016."},{"key":"133_CR6","first-page":"CD003262","volume":"4","author":"EJ Zuuren van","year":"2015","unstructured":"van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MMD, Charland L. Interventions for rosacea. Cochrane Database Syst Rev. 2015;4:CD003262.","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"133_CR7","first-page":"316","volume":"13","author":"L Stein","year":"2014","unstructured":"Stein L, Kircik L, Fowler J, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13(3):316\u201323.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"133_CR8","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.13408","volume":"172","author":"A Taieb","year":"2015","unstructured":"Taieb A, Ortonne JP, Ruzicka T, et al. Ivermectin Phase III study group. Superiority of ivermectin 1% cream over metronidazole 0\u00b775% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015;172(4):1103\u201310.","journal-title":"Br J Dermatol"},{"issue":"5","key":"133_CR9","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/jdv.13537","volume":"30","author":"A Taieb","year":"2016","unstructured":"Taieb A, Khemis A, Ruzicka T, et al. Ivermectin Phase III Study Group. Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study. J Eur Acad Dermatol Venereol. 2016;30(5):829\u201336.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"133_CR10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy"},{"key":"133_CR11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"28","key":"133_CR12","first-page":"1574","volume":"149","author":"LM Lamers","year":"2005","unstructured":"Lamers LM, Stalmeier PF, McDonnell J, Krabbe PF, van Busschbach JJ. Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff]. [Article in Dutch. Ned Tijdschr Geneeskd. 2005;149(28):1574\u20138.","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"6","key":"133_CR13","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s11136-004-7713-0","volume":"14","author":"SJ Walters","year":"2005","unstructured":"Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14(6):1523\u201332.","journal-title":"Qual Life Res"},{"issue":"1","key":"133_CR14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MK Basra","year":"2015","unstructured":"Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27\u201333.","journal-title":"Dermatology"},{"key":"133_CR15","unstructured":"Stein Gold L, Kircik L, Fowler J, et al. Ivermectin Phase 3 Study Group. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol. 2014;13(11):1380\u20136."},{"issue":"2","key":"133_CR16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.cgh.2015.09.013","volume":"14","author":"WQ Li","year":"2016","unstructured":"Li WQ, Cho E, Khalili H, Wu S, Chan AT, Qureshi AA. Rosacea, use of tetracycline, and risk of incident inflammatory bowel disease in women. Clin Gastroenterol Hepatol. 2016;14(2):220\u20135.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"3","key":"133_CR17","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S1473-3099(15)00527-7","volume":"16","author":"TR Walsh","year":"2016","unstructured":"Walsh TR, Efthimiou J, Dr\u00e9no B. Systematic review of antibiotic resistance in acne: an increasing topical and oral threat. Lancet Infect Dis. 2016;16(3):e23\u201333.","journal-title":"Lancet Infect Dis."},{"issue":"6","key":"133_CR18","first-page":"573","volume":"7","author":"JQ Rosso Del","year":"2008","unstructured":"Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008;7(6):573\u20136.","journal-title":"J Drugs Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-016-0133-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T01:32:15Z","timestamp":1589679135000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13555-016-0133-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,18]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["133"],"URL":"https:\/\/doi.org\/10.1007\/s13555-016-0133-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,18]]}}}